Industries > Pharma > Dermatological Drugs Market Forecast 2017-2027
Dermatological Drugs Market Forecast 2017-2027
Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma
The revenue of the dermatological drugs market in 2016 is estimated at $25.65bn and is expected to grow at a CAGR of 4.5% in the first half of the forecast period. Psoriasis drugs accounted for the largest share of the market in 2016, this segment generated $9.23bn.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 295-page report you will receive 111 tables and 92 figures – all unavailable elsewhere.
The 295-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Dermatological drugs market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the main submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis
• Analysis of the Psoriasis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx
• Analysis of the Skin Infections drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban
• Analysis of the Acne drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx
• Analysis of the Dermatitis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• US
• Germany
• France
• UK
• Italy
• Spain
• Japan
• China
• Brazil
• Russia
• India
• Rest of World
• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
• Our study includes SWOT analysis and Porter’s Five Force analysis of the dermatological drugs market.
• Two interviews conducted by Visiongain with experts in the dermatological drugs market:
• Interview with Dr Michael Siegel, Vice President of Research Programs at National Psoriasis Foundation
• Interview with Guillaume Clement, Executive Vice President, Region EUROPE+, LEO Pharma
• Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
• Galderma (Nestle Skin Health S.A.)
• Johnson & Johnson
• AbbVie
• GlaxoSmithKline (GSK)
• Pfizer
• LEO Pharma
Our new report discusses issues and events affecting the dermatological drugs market:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations
• Launches of new drug categories
• Biosimilars approvals, Biosimilars interchangeability, Biosimilars guidance
Visiongain’s study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.
Buy our report today Dermatological Drugs Market Forecast 2017-2027: Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. An Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction to Dermatology
2.2.1 The Structure of Skin, Hair, and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.3.1 Acne: The Most Common Skin Disease
2.3.1.1 Acne: Epidemiology
2.3.1.2 Acne: Causes and Pathogenesis
2.3.1.3 Acne: Treatment
2.3.2 Dermatitis: Inflammation of the Skin
2.3.2.1 Atopic Dermatitis
2.3.2.2 Contact Dermatitis
2.3.2.3 Seborrhoeic Dermatitis
2.3.2.4 Nummular Dermatitis
2.3.2.5 Perioral Dermatitis
2.3.3 Psoriasis: A Complex Multi-factorial Disease
2.3.4 Rosacea: Vascular Instability
2.3.5 Alopecia: Excessive Shedding Of Hair
2.4 Skin Infections: A Serious Healthcare Threat
2.4.1 Bacterial Skin Infections
2.4.2 Fungal Skin Infections
2.4.3 Viral Skin Infections
2.5 Common Skin Treatments
2.5.1 Creams and Semisolid Emulsions
2.5.2 Ointments
2.5.3 Lotions
2.5.4 Solutions
2.5.5 Occlusive Therapy
2.5.6 Cleansing Agents
2.5.7 Powders and Hydrophilic Polymer
2.5.8 Anti-Infective Agents
2.5.9 Anti-Inflammatory Agents
2.6 Phases of Clinical Trials
2.7 Dermatological Drugs: Market Definition in this Report
3. The Global Dermatological Drugs Market, 2017-2027
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation of the Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market in 2016
3.4 The Global Dermatological Drugs Market: Market Forecast 2017-2027
3.5 Dermatological Drugs: Changing Market Shares by Sector 2017-2027
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2017-2027
4.1 Psoriasis Treatments: The Dominance of Biologics
4.1.1 Leading Products in the Psoriasis Drugs Market, 2016
4.2 Psoriasis: Market Trends and Developments, 2017
4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
4.2.3 Biosimilars and Interchangeables
4.2.3.1 Extrapolation of indications
4.2.3.2 Biosimilar interchangeability in the EU
4.2.3.3 Biosimilar guidance in the US
4.2.4 The Disadvantages of Biologics in Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2017-2027
4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2016-2027
4.4 Leading Drugs Used in the Treatment of Psoriasis
4.4.1 Humira (adalimumab) - AbbVie
4.4.1.1 Humira: Historical Sales Analysis, 2010-2015
4.4.1.2 Humira: Sales Forecast 2017-2027
4.4.1.3 Future Prospects for Biosimilar Versions of Humira
4.4.2 Stelara (ustekinumab) – Johnson & Johnson
4.4.2.1 Stelara New Market Leader, Ahead of Humira
4.4.2.2 Stelara: Historical Sales Analysis, 2010-2015
4.4.2.3 Stelara: Sales Forecast 2017-2027
4.4.2.4 Intensifying Competition for Stelara
4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
4.4.3.2 Enbrel: Historical Sales Analysis, 2008-2016
4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2017-2027
4.4.3.4 Patent Litigation with Sandoz Over Enbrel
4.4.3.5 Enbrel: Sales Forecast 2017-2027
4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
4.4.3.7 Competition from Other Drugs
4.4.3.8 Biosimilar Competition for Enbrel
4.4.4 Remicade (infliximab) – Johnson & Johnson
4.4.4.1 Remicade: Historical Sales Analysis, 2008-201
4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2017-2027
4.4.4.3 Remicade: Sales Forecast 2017-2027
4.4.5 Taltz (ixekizumab) – Eli Lily
4.4.5.1 Taltz: Sales Forecast 2017-2027
4.4.6 Otezla (apremilast) – Celgene
4.4.6.1 Otezla: Sales Forecast 2017-2027
4.4.7 Cosentyx (secukinumab) - Novartis
4.4.7.1 Cosentyx: Sales Forecast 2017-2027
4.4.8 Other Psoriasis Drugs
4.4.8.1 Cimzia (certolizumab) - UCB
4.4.8.2 Sorilux (calcipotriene foam) - GSK
4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma
4.4.8.3 Other Psoriasis Drugs: Sales Forecast 2017-2027
4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2017-2027
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products in the Skin Infection Drugs Market, 2016
5.2 Skin Infection Drugs: Market Forecast 2017-2027
5.2.1 Skin Infection Drugs: Changing Market Shares by Leading Drugs 2017-2027
5.3 Leading Drugs Used in the Treatment of Skin Infections
5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
5.3.2 Acquisition by Merck & Co
5.3.3 Generic Competition for Cubicin
5.3.4 Cubicin: Sales Forecast 2017-2027
5.3.5 Lifecycle Management Strategies for Cubicin
5.4 Zyvox (linezolid) - Pfizer
5.4.1 Zyvox: Historical Sales Analysis, 2010-2015
5.4.2 Zyvox: Sales Forecast 2017-2027
5.4.3 The Threats to Zyvox Sales from Competing New Drugs
5.5 Canesten (clotrimazole) - Bayer
5.5.1 Canesten: Historical Sales Analysis, 2011-2015
5.5.2 Canesten: Sales Forecast 2017-2027
5.6 Valtrex (valaciclovir) - GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2015
5.6.2 Valtrex: Sales Forecast 2017-2027
5.7 Bactroban (mupirocin) - GSK
5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
5.7.2 Bactroban: Sales Forecast 2017-2027
5.8 Lamisil (terbinafine) - Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2017-2027
5.9 Other Skin Infection Drugs
5.9.1 Dalvance (dalbavancin) - Durata Therapeutics
5.9.2 Jublia (efinaconazole) - Valeant
5.9.3 Kerydin (tavaborole) - Anacor
5.9.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.9.5 Zovirax (acyclovir) - Valeant/GSK
5.9.5.1 Valeant Acquires Zovirax in US and Canada
5.9.5.2 Mylan’s Generic Zovirax and Actavis’ Authorised Generic
5.9.6 Other Skin Infection Drugs: Sales Forecast 2017-2027
5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2017-2027
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products in the Acne Drugs Market, 2016
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise of Combination Therapies in Acne Treatment
6.2.2 Oral Contraceptives in Treating Acne
6.2.3 The Threat of Generic Competition in the Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2017-2027
6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2016-2027
6.4 Leading Drugs in the Acne Drugs Market
6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.4.1.1 Epiduo: Sales Forecast 2017-2027
6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
6.4.1.3 Paediatric Approval for Epiduo
6.4.2 Solodyn (minocycline) - Valeant
6.4.2.1 Solodyn: Sales Forecast 2017-2027
6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals
6.4.2.3 Impax and Medicis Collaborating On Advanced Solodyn
6.4.2.4 Medicis and Lupin Settle
6.4.3 Claravis (isotretinoin) - Teva
6.4.3.1 Claravis: Sales Forecast 2017-2027
6.4.4 Aczone (dapsone) - Allergan
6.4.4.1 Aczone: Sales Forecast 2017-2027
6.4.5 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.4.5.1 Recent Generic Competition to Differin
6.4.5.2 Differin: Sales Forecast 2017-2027
6.4.5.3 Adapalene Gel to be Available OTC in the US
6.4.5.4 Federal Circuit Court Invalidates Differin Patents
6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/Sun Pharma
6.4.6.1 Absorica/Epuris: Sales Forecast 2017-2027
6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.4.7.1 Valeant’s Patent Settlement with Actavis over Ziana
6.4.7.2 Ziana: Sales Forecast 2017-2027
6.4.8 Doryx (doxycycline) – Actavis/Mayne Pharma
6.4.8.1 Lifecycle Management Strategies for Doryx
6.4.8.2 Divestment Agreement with Mayne Pharma
6.4.8.3 Generic Competition for Doryx
6.4.8.4 Doryx: Sales Forecast 2017-2027
6.4.9 Other Acne Drugs
6.4.9.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, and Watson
6.4.9.2 Amnesteem (isotretinoin) - Mylan
6.4.9.2.1 Amnesteem: Financial Analysis
6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer
6.4.9.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.4.9.5 Veltin (tretinoin/clindamycin) - GSK
6.4.9.6 Other Acne Drugs: Sales Forecast 2017-2027
6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2017-2027
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products in the Dermatitis Drugs Market, 2016
7.2 Dermatitis Drugs: Market Forecast 2017-2027
7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2017-2027
7.3 Leading Drugs in the Dermatitis Drugs Market
7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer
7.3.1.1 Bepanthen: Sales Forecast 2017-2027
7.3.2 Elocon (mometasone) - Merck & Co
7.3.2.1 Elocon: Sales Forecast 2017-2027
7.3.3 Protopic (tacrolimus) – LEO Pharma
7.3.3.1 Protopic Benefits from Expanded Indication
7.3.3.2 Generic Competition For Protopic
7.3.3.3 Protopic: Sales Forecast 2017-2027
7.3.4 Dermovate -GSK
7.3.4.1 Dermovate: Sales Forecast 2017-2027
7.3.5 Other Dermatitis Drugs: Sales Forecast 2017-2027
7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets for Dermatological Drugs, 2017-2027
8.1 The Dermatological Drugs Market by Region
8.1.1 The Global Distribution of Dermatological Drugs in 2016
8.2 Leading National Markets: Forecast 2017-2027
8.2.1 Changing Market Shares by Region, 2016-2027
8.3 Regional Dermatological Drugs Markets: Analysis and Forecasts, 2016-2027
8.3.1 United States: The Largest Dermatological Drugs Market
8.3.1.1 Obamacare Repeal
8.3.1.2 Legislative Environment Stimulating Biosimilars Market?
8.3.1.3 Biosimilar Interchangeability guidance in the US
8.3.1.4 US Dermatological Drugs Market: Market Forecast 2017-2027
8.3.2 The EU5 Markets: Growth Expected in Each Country
8.3.2.1 EU5 Dermatological Drugs Market: Market Forecast 2017-2027
8.3.2.1.1 EU5 Markets: Changing Market Shares by Country, 2016-2027
8.3.2.2 Germany
8.3.2.2.1 German Dermatological Drugs Market: Market Forecast 2017-2027
8.3.2.3 France
8.3.2.3.1 French Dermatological Drugs Market Forecast 2017-2027
8.3.2.4 UK
8.3.2.4.1 The Impact Of Brexit On The Dermatological Drugs Industry
8.3.2.4.1.1 Pricing and Reimbursement
8.3.2.4.1.2 New Regulatory Body and Clinical Trials
8.3.2.4.1.3 Patent Protection
8.3.2.4.1.4 Research and Funding
8.3.2.4.2 UK Dermatological Drugs Market Forecast 2017-2027
8.3.2.5 Italy
8.3.2.5.1 Italian Dermatological Drugs Market Forecast 2017-2027
8.3.2.6 Spain
8.3.2.6.1 Spanish Dermatological Drugs Market Forecast 2017-2027
8.3.3 Japan
8.3.3.1 The Cost of Treatment in Japan
8.3.3.2 Japanese Pharmaceutical Industry Regulatory Reform
8.3.3.3 Japanese Dermatological Drugs Market Forecast 2017-2027
8.3.4 China
8.3.4.1 Expansion of Healthcare Coverage and Reimbursement in China
8.3.4.2 Improving Public Perception of Dermatology in China
8.4.3.3 Price Controls and the Anhui Model
8.3.4.4 Chinese Dermatological Drugs Market Forecast 2017-2027
8.3.5 India
8.3.5.1 The Effects of the Drug Prices Control Order of 2013
8.3.5.2 India’s Expansion of Healthcare Provision
8.3.5.3 Revised Biosimilar Guidelines
8.3.5.4 Indian Dermatological Drugs Market Forecast 2017-2027
8.3.6 Brazil
8.3.6.1 The Growth in Brazil’s Healthcare Landscape
8.3.6.2 Clearer Access to Medicines in Brazil
8.3.6.3 Brazilian Dermatological Drugs Market Forecast 2017-2027
8.3.7 Russia
8.3.7.1 Pharma2020 Strategy - Healthcare and Industry Reform
8.3.7.2 Russian Dermatological Drugs Market Forecast 2017-2027
8.3.8 Rest of the World
8.3.8.1 The Rest of the World Dermatological Drugs Market Forecast 2017-2027
9. Leading Companies in the Dermatological Drugs Market, 2017-2027
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2017
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition of Galderma
9.2.2.2 Approval and Launch of Soolantra for Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2016
9.3.2 Johnson & Johnson: Dermatological Drug Development
9.3.2.1 Pipeline, 2017
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2017
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2017
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2016
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2017
9.6.2 Pfizer: Acquisition of Anacor
9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2017
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2017
9.7.2 LEO Pharma: Dermatological Drugs Development Pipeline, 2017
9.7.3 LEO Pharma: Strategic Partnership with AstraZeneca
9.7.4 LEO Pharma: Acquisition of Astellas Pharma
10. Dermatological Drugs: Research and Development Pipeline, 2017-2027
10.1 Innovative Products Currently in Development Will Drive Growth
10.1.1 New Technology in R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms and Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2017
10.2.1 Psoriasis Drugs in Phase 3 Development or Regulatory Approval Stage
10.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma
10.2.2 Psoriasis Drugs in Phase 2 Development
10.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly
10.2.2.2 PH-10 (Rose Bengal) - Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2017
10.3.1 Drugs in Phase 3 Development for Skin Infections
10.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals
10.3.1.2 NB-001 - NanoBio Corporation
10.3.1.3 Luliconazole - Topica Pharmaceuticals
10.3.2 Drugs in Phase 2 Development for Skin Infections
10.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
10.4 Acne Drugs Development Pipeline, 2017
10.4.1 Drugs in Phase 3 Development for Acne
10.4.1.2 Visonac (photodynamic therapy) - Photocure
10.4.2 Drugs in Phase 2 Development for Acne
10.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
10.4.4 A Possible Vaccine for Acne
10.5 Dermatitis Drugs Development Pipeline, 2017
10.5.1 Drugs in Phase 3 Development for Dermatitis
10.5.1.1 Toctino (alitretinoin) - GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) - Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) - Regeneron/ Sanofi
10.5.2 Drugs in Phase 2 Development for Dermatitis
10.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2017
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera
10.6.1.3 Mirvaso (brimonidine) - Galderma
10.6.1.4 Picato (ingenol mebutate) - LEO Pharma
10.6.1.5 Xolair (omalizumab) - Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2017
10.6.2.1 CD5024 (ivermectin) - Galderma
10.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E Herbal Biotechnology
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2017
11. Qualitative Analysis of the Dermatological Drugs Market, 2017-2027
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis of the Global Dermatological Drugs Market, 2017-2027
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need in Dermatology
11.2.1.2 A Healthy Pipeline of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy and Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge to Treatment Design
11.2.2.3 Impending Patent Expiries and the Challenges Posed by Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors in Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances in Genomics
11.2.3.3 Advances in Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertainty Surrounding Reimbursement and Payment Approvals
11.2.4.2 The Rising Cost of Research and Development
11.2.4.3 Downward Pressures on Drug Prices
11.3 Porter’s Five Force Analysis of the Global Dermatological Drugs Market, 2017-2027
11.3.1 Threat of New Entrants
11.3.2 Threat of Substitutes
11.3.3 Rivalry among Competitors
11.3.4 Power of Buyers
11.3.5 Power of Suppliers
12. Research Interviews
12.1 Interview with Dr Michael Siegel, Vice President of Research Programs at National Psoriasis Foundation
12.1.1 National Psoriasis Foundation
12.1.2 Future of the Dermatology Drugs Market
12.1.3 Future Developments on Psoriatic Disease Treatment
12.1.4 New Therapies Arising from Stem Cell Research
12.1.5 Limitations and Scope in Developing Biomarkers for Psoriatic Disease
12.2 Interveiw With Guillaume Clement, Executive Vice President, Region EUROPE+, LEO Pharma
12.2.1 LEOPharma
12.2.2 Future of the Dermatology Drugs Market
12.2.3 Trends – Mergers and Acquisitions in the Pharmaceutical Industry
12.2.4 Leo Pharma’s Acquisition of Astellas Pharma
12.2.5 Novel Biologic Treatments for Psoriasis, Partnership with AstraZeneca
13. Conclusions
13.1 Overview of Current Market Conditions and Market Forecast, 2016-2027
13.2 Leading Sectors in Dermatological Drugs in 2016
13.3 Leading Regions in the Dermatological Drugs Market in 2016
13.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2017-2027
13.5 What Does the Future Hold For Dermatological Drugs?
14. Glossary
Associated Visiongain Reports
Appendix A
About Visiongain
Appendix B
Visiongain Report Evaluation Form
List of Tables
Table 1.1 Dermatological Drugs Market Forecast by National Markets: Revenue ($bn), AGR (%) and CAGR (%), 2017-2027
Table 2.1 Clinical Trial Phases, 2016
Table 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn) and Market Shares (%), 2016
Table 3.2 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2021, 2021-2027, 2016-2021
Table 3.4 The Global Dermatological Drugs Market by Sector: Market Share (%), 2016, 2021 and 2027
Table 4.1 Top Drugs in The Psoriasis Drugs Market: Revenue ($bn) and Market Shares (%), 2016
Table 4.2 Psoriasis Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
Table 4.4 Humira Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
Table 4.5 Humira AbbVie Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.6 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
Table 4.7 Stelara Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.8 Enbrel Historical Sales by Company: Revenue ($bn) and AGR (%), 2008-2016
Table 4.9 Enbrel Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.10 Remicade Historical Sales: Revenue ($bn), 2010-2016
Table 4.11 Remicade Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.12 Taltz: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.13 Otezla Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.14 Cosentyx Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.15 Other Psoriasis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn) and Market Share (%), 2016
Table 5.2 Skin Infection Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
Table 5.4 Cubicin Sales Forecast: Revenue($bn), AGR (%) and CAGR(%), 2016-2027
Table 5.5 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
Table 5.6 Zyvox: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.7 Canesten: Historical Sales: Revenue ($bn), and AGR (%), 2011-2015
Table 5.8 Canesten: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.9 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
Table 5.10 Valtrex: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.11 Bactroban: Historical Sales: Revenue ($bn) and AGR (%), 2010-2013
Table 5.12 Bactroban Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.13 Lamisil Novartis Sales Forecast: Revenue ($bn), AGR (%), and CAGR (%), 2016-2027
Table 5.14 Other Skin Infection Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn) and Market Share (%), 2016
Table 6.2 Acne Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
Table 6.4 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 6.5 Solodyn (Valeant) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 6.6 Claravis (Teva) Sales Forecast: Revenue ($bn), AGR%, and CAGR (%), 2016-2027
Table 6.7 Aczone (Allergan) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 6.8 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR%), 2016-2027
Table 6.9 Absorica/Epuris Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%),
2016-2027
Table 6.10 Ziana Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 6.11 Doryx Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 6.12 Other Acne Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 7.1 Top Drugs in The Dermatitis Drugs Market: Revenue ($bn) and Market Share (%), 2016
Table 7.2 Dermatitis Drugs Market: Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2016, 2021, 2027
Table 7.4 Bepanthen/Bepanthol Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 7.5 Elocon Sales Forecast: Revenue ($bn), AGR (%) CAGR (%), 2016-2027
Table 7.6 Protopic Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 7.7 Dermovate Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 7.8 Other Dermatitis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn) and Market Share (%), 2016
Table 8.2 Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2016-2027
Table 8.3 The Global Dermatological Drugs Market Forecast by Region: CAGR (%), 2016-2021, 2021-2027, and 2016-2027
Table 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2016, 2021 and 2027
Table 8.5 The US Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.6 US Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.7 The EU5 Dermatological Drugs Market by Country Revenue ($bn) and Market Share (%), 2016
Table 8.8 The EU5 Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2016, 2021 and 2027
Table 8.10 The German Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.13 The French Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%)and CAGR (%), 2016-2027
Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.15 The UK Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.17 The Italian Dermatological Drugs Market Forecast: ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.19 The Spanish Dermatological Drugs Market Forecast: Revenue($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.21 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.23 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%) and CAGR (%), 2016-2027
Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.25 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.27 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
Table 8.29 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 8.30 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), Market Share (%) and CAGR (%), 2016-2027
Table 8.31 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 9.1 Galderma: Company Overview, 2016
Table 9.2 Johnson & Johnson: Company Overview, 2016
Table 9.3 AbbVie: Company Overview, 2017
Table 9.4 GlaxoSmithKline: Company Overview, 2016
Table 9.5 GlaxoSmithKline: Dermatological Drugs Pipeline, 2016
Table 9.6 Pfizer: Company Overview, 2016
Table 9.7 LEO Pharma: Company Overview, 2016
Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2016
Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2016
Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2016
Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026
Table 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2016, 2021 and 2027
Table 12.2 The Global Dermatological Drugs Market by Sector: Market Size($bn) and Market Shares (%), 2016
Table 12.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2016, 2021 and 2027
Table 12.4 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2016, 2021, 2027
List of Figures
Figure 1.1 Global Dermatological Drugs Market: Market Sectors, 2017
Figure 2.1 Anatomy of Human Skin
Figure 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn), 2016
Figure 3.2 The Global Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%) 2016-2027
Figure 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2021
Figure 3.4 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2021-2027
Figure 3.5 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2027
Figure 3.6 The Global Dermatological Drugs Market by Sector: Market Share (%), 2016
Figure 3.7 The Global Dermatological Drugs Market by Sector: Market Share (%), 2021
Figure 3.8 The Global Dermatological Drugs Market by Sector: Market Share (%), 2027
Figure 4.1 Top Drugs in The Psoriasis Drugs Market: Revenue ($bn), 2016
Figure 4.2 Psoriasis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2016
Figure 4.4 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%) by Leading Drugs, 2021
Figure 4.5 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2027
Figure 4.6 Humira Historical Sales: Revenue ($bn) AGR (%), 2010-201
Figure 4.7 Humira AbbVie Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.8 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
Figure 4.9 Stelara Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.10 Enbrel Historical Sales by Company: Revenue ($bn), 2008-2015
Figure 4.11 Enbrel Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.12 Remicade Historical Sales: Revenue ($bn) and AGR (%), 2008-2016
Figure 4.13 Remicade Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.14 Taltz Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.15 Otezla Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.16 Cosentyx Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.17 Other Psoriasis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn), 2016
Figure 5.2 Skin Infection Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2016
Figure 5.4 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2021
Figure 5.5 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2027
Figure 5.6 Cubicin Sales Forecast: Revenue ($bn) AGR (%), 2016-2027
Figure 5.7 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
Figure 5.8 Zyvox: Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.9 Canesten: Historical Sales: Revenue ($bn) and AGR (%), 2011-2014
Figure 5.10 Canesten: Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.11 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
Figure 5.12 Valtrex Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.13 Bactroban: Historical Sales: Revenue ($bn) AGR (%), 2010-2013
Figure 5.14 Bactroban Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.15 Lamisil Novartis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.16 Other Skin Infection Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn), 2016
Figure 6.2 Acne Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2016
Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2021
Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2027
Figure 6.6 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.7 Solodyn (Valeant) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.8 Claravis (Teva) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.9 Aczone (Allergan) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.10 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.11 Absorica/Epuris Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.12 Ziana Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.13 Doryx Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.14 Other Acne Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 7.1 Top Drugs in The Dermatitis Drugs Market: Revenue ($bn), 2016
Figure 7.2 Dermatitis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2016
Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2021
Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2027
Figure 7.6 Bepanthen/ Bepanthol Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 7.7 Elocon Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 7.8 Protopic Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 7.9 Dermovate Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 7.10 Other Dermatitis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn), 2016
Figure 8.2 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2016
Figure 8.3 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2021
Figure 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2027
Figure 8.5 US Dermatological Drugs Market Forecast: Revenue ($bn) AGR (%), 2016-2027
Figure 8.6 The EU5 Dermatological Drugs Market by Country: Revenue ($bn), 2016
Figure 8.7 Germany, France, UK, Italy, and Spain Dermatological Drugs Market Forecast: Revenue ($bn), 2016-2027
Figure 8.8 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2016
Figure 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2021
Figure 8.10 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2027
Figure 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.13 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2016-2027
Figure 8.14 The Italian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.15 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.16 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.17 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.18 The Indian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.19 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.20 The Russian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 8.21 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 11.1 Porter’s Five Force Analysis of the Dermatological Drugs Market, 2016
Figure 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), 2016, 2021, 2027
Figure 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn), 2016
Figure 12.3 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2016, 2021, 2027
Abbott
AbbVie
Actavis
AET BioTech
Alkem Laboratories
Allergan
Almirall
Amgen
Anacor
Ascend Therapeutics
Astellas
Aurovindo
Barr Labs
Bayer
Betta Pharmaceuticals
Biocon/Mylan
Biofrontera
Biogen
Biovail Laboratories
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Brazilian Society of Dermatology
Cadila Healthcare
Can-Fite BioPharma
Cassiopea SpA
Celgene
Celltrion
Cempra
Cipher Pharmaceuticals
Cipla
Cubist Pharmaceuticals
Cutanea Life Sciences
Dow Pharmaceuticals Science
Dr Reddy’s
Durata Therapeutics
Eisai
Eli Lilly
European Medicines Agency (EMA)
European Pharmaceutical Market Research Association (EPhMRA)
Food and Drug Association (FDA)
Foamix
Fougera
Fujifilm
G&E Herbal Biotechnology
Galderma
GlaxoSmithKline
Glenmark Pharmaceuticals
Heritage
Impax
Incyte
Janssen Biotech
Johnson & Johnson
Kyowa Hakko Kirin
L’Oreal
LEO Pharma
Lupin
Maruho
Mayne Pharma
Medicis
Medison Pharma
Melinta Pharmaceuticals
Merck
Merz Pharmaceuticals
Mitsubishi Tanabe
MorphoSys
Mylan
NanoBio Corporation
National Psoriasis Foundation (NPF)
NeoStrata Compnay Inc
Nestle Skin Health
Novan
Novartis
Perriogo
Pfizer
PharmaPraxis
Photocure
Pierre Fabre
Provectus Biopharmaceuticals
QLT Inc
Ranbaxy
Regeneron Pharmaceuticals
Roche
Samsung Bioepis
Samsung BioLogics
Sandoz
Sanofi
Schering-Plough
Shanghai CP Buojian Pharmaceutical
Sidmak Labs
Sol-Gel Technologies Ltd
Sun Pharma
Sunovion
Takeda
Tanabe
Tanja Todberg
Taro Pharmaceuticals
Teva
Thesan Pharmaceuticals Inc
Topica Pharmaceuticals
UCB
Valeant
Vical
Warner Chilcott
Watson Pharmaceuticals
Xenon Pharmaceuticals
Zydus
Download sample pages
Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2017-2027Download sample pages
Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2017-2027Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
